| Identifier |
20220215_nanos_sciplatform3_01 |
| Title |
Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease |
| Creator |
Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas |
| Affiliation |
(PSS) University of Colorado, Aurora, CO; (SS) (RH) Horizon Therapeutics plc, Deerfield, IL; (RSD) Cedars Sinai Medical Center Los Angeles; Shanghai International Medical Center |
| Subject |
Neuro-ophthalmology & Systemic Disease (eg. MS, MG, Thyroid); Graves' Disease |
| Description |
Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non- responders could receive a course of teprotumumab in the OPTIC-X study. This analysis examined sustainability of response over the follow-up periods from the phase 2, OPTIC and OPTIC-X studies, including the recently proposed EUGOGO composite outcome. |
| Date |
2022-02 |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Source |
2022 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2022: Scientific Platform III |
| Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
| Publisher |
North American Neuro-Ophthalmology Society |
| Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Rights Management |
Copyright 2022. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6p2gs47 |
| Setname |
ehsl_novel_nam |
| ID |
2201917 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6p2gs47 |
